Seguridad y eficacia en el uso de corticoides | 24 SEP 17

Manejo del asma grave difícil de tratar

Opciones para pacientes asmáticos que requieren el uso continuo o frecuente de corticoides orales.
INDICE:  1. Página 1 | 2. Rferencias bibliográficas
Rferencias bibliográficas

1 British Thoracic Society. 2016 and Scottish Intercolegiate Guidelines Network. British guideline on the management of asthma. www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-uideline-2016/.

2 Global Initiative for Asthma (GINA). 2016. Global strategy for asthma management and prevention. http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-managementand-prevention/

3 Asthma UK. 2016. Asthma facts and statistics. www.asthma.org.uk/about/media/factsand-statistics/.

4 Health and Social Care Information Centre. 2015. Quality and Outcomes Framework–prevalence, achievements and exceptions report. England, 2014-15. http://content.digital.nhs.uk/catalogue/PUB18887/qof-1415-Report%20v1.1.pdf.

5 England NHS. 2016. 2013/14 NHS standard contract for respiratory: severe asthma (adult). www.england.nhs.uk/wp-content/uploads/2013/06/a14-respiratory-sev-asthma.pdf.

6 Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. Asthma and Allergy Research Group of the National Heart and Lung Institute. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003;358:478-83. doi:10.1183/09031936.03. 00017003 pmid:14516138.

7 Royal College of Physicians. 2014. Why asthma still kills. www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills.

8 Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir Med 2011;358:1308-15. doi:10.1016/j.rmed.2011.03.019 pmid:21511454.

9 Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;358:1139-51. doi:10.1016/j.rmed.2006.03.031 pmid:16713224.

10 Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014;358:CD003559.pmid:24414989.

11 Gibeon D, Menzies-Gow A. Recent changes in the drug treatment of allergic asthma. Clin Med (Lond) 2013;358:477-81. doi:10.7861/clinmedicine.13-5-477 pmid:24115705.

12 Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;358:343-73.doi:10.1183/09031936.00202013 pmid:24337046.

13 Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;358:CD002993.pmid:11406057.

14 Evans DJ, Cullinan P, Geddes DM. Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2001;358:CD002985.pmid:11406053.

15 Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev 2000;358:CD000391.pmid:10796540.

16 Dean T, Dewey A, Bara A, Lasserson TJ, Walters EH. Azathioprine as an oral corticosteroid sparing agent for asthma. Cochrane Database Syst Rev 2004;358:CD003270.pmid:14974011.17 National Institute for Health and Care Excellence. TA278: Omalizumab for treating severe persistent allergic asthma (NICE technology appraisal guidance 278). 2013. www.nice.org.uk/guidance/TA278.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024